Image

Fast Track to Fertility

Fast Track to Fertility

Recruiting
18 years and older
Female
Phase N/A

Powered by AI

Overview

The Fast Track to Fertility (FTF) program is an algorithmic text messaging communication and patient education platform designed to improve the efficiency the fertility workup. The initial pilot program resulted in an approximately 50% reduction in the time taken to complete the diagnostic workup. Since the pilot program, the investigators have enhanced the FTF Program (v2.0) beyond the texting platform, incorporating educational videos to increase patient knowledge and autonomy in the workup and treatment of infertility. This protocol pertains to a randomized controlled quality improvement initiative to measure the impact of the FTF v2.0 Program on fertility workup completion, efficiency, and patient outcomes.

Description

Infertility, recognized as a disease by the WHO, is defined as the failure to achieve successful pregnancy after at least 12 months of regular unprotected intercourse in women younger than age 35, or within 6 months in women 35 or older. The worldwide prevalence of infertility is high, affecting approximately 12-18% of couples. Through detailed medical history for risk factors, assessment of ovulatory function, structure and patency of the female reproductive tract, and semen analysis of the male partner, the cause of infertility can be ascertained in most patients and allows determination of appropriate therapeutic options.

Despite the high prevalence of infertility, only a small proportion of patients seek care, and an even smaller number continue care after the initial evaluation. Several studies have examined underlying reasons for early discontinuation of infertility care, namely prior to initiation of treatment. In a study from the Netherlands examining drop-out rates at different stages of fertility care, nearly half of the patients who discontinued care withdrew before initiating any treatment; 6.0% did not return after the first visit, 3.4% dropped out during the diagnostic work-up, and 35.7% dropped out after finishing the diagnostic workup. In a cohort of 434 infertile couples residing in urban United States, Eisenberg et al found that 13% did not pursue any infertility treatment after the initial consultation with a reproductive endocrinologist. When compared to patients pursuing treatment, these patients were typically older, less educated, of lower socioeconomic status, and had a higher baseline depression score. Of note, psychological factors are associated with higher drop-out rates even in patients with insurance coverage for infertility treatments. This data highlights that the initial evaluation and diagnostic work-up process is a critical stage of fertility care that engages patients and influences their decision to pursue treatment.

Although the barriers to pursuing fertility treatments have been studied, there is less information on the precise barriers to completing the diagnostic work-up. This first step can be cumbersome as it includes laboratory tests and radiographic or ultrasound imaging to evaluate the fallopian tube patency and uterine cavity in the female partner, blood tests and semen analysis in the male partner, and more recently, genetic carrier screening in both partners. What adds to the complexity of this testing is the need for time-sensitive and menstrual-cycle dependent testing which is required for the physician to recommend a personalized treatment plan. Poor communication or lack of understanding of the instructions can lead to missed testing windows, especially follicular phase appointments for blood tests and imaging studies. From a patient's perspective, each month that passes represents a missed opportunity to become pregnant further contributing to the higher levels of anxiety and stress associated with infertility diagnosis.

Based on contextual inquiry and grounded in patient needs, the work-up period was identified as an opportunity to optimize patient interactions with their physician. It was hypothesized that the implementation of a novel digital health platform to improve communication with patients regarding their diagnostic work-up will improve completion rates and overall patient retention. To this effect, the Fast Track to Fertility (FTF) program was created, which was developed using AI and natural language processing (NLP) to accurately provide semi-automated two-way text message communications to send reminders regarding the timing of tests, location of testing sites, and related educational materials. A detailed description of the discovery, pilot, and semi-automation phases of this innovative program has been published previously. A text-based approach was selected as it does not require downloading an app, supports real-time two-way engagement in a private setting, and has been shown to reduce racial disparities in care for reproductive-age women in our department.

The initial pilot program coupled with the iterative development phases resulted in an approximately 50% reduction in the time taken to complete the fertility work-up (from 97 days to 41 days) with high patient net promoter scores (>70%). In addition, high patient willingness to participate in this program (70%) and high accuracy of the AI-augmented texting (up to 80%) was observed, resulting in workflow improvement for staff and providers. However, it is not clear if these favorable outcomes were at least in part related to selection bias, as patients had to opt into the program and were not randomized. A secondary analysis on the barriers to infertility workup completion demonstrated that more Black women and those without fertility benefits both declined to enroll in the FTF program and did not initiate the infertility workup.

The goal of this proposed quality improvement initiative is to perform a randomized controlled quality improvement study on the updated FTF program (FTF v2.0). Since the initial pilot study was published, the FTF Program has been reworked. The platform now uses an algorithmic approach to text messaging (rather than AI) and incorporates several educational videos to increase patient knowledge and autonomy in the workup and treatment of infertility. Through this initiative, the aim is to measure the impact of the FTF program on infertility workup completion, fertility treatment initiation, pregnancy, and live birth.

Eligibility

Inclusion Criteria:

  • Female new patients seen at Penn Fertility Care for the workup of infertility
  • Patients who have yet to complete at least 3 components of the fertility workup,
    including
    1. Laboratory blood tests
    2. Tubal patency testing / uterine cavity assessment (hysterosalpingogram (HSG) or sonohysterogram (Femvue))
    3. Pelvic ultrasound
    4. Semen analysis
    5. Genetic carrier screening.
  • Patients must be willing to be randomized to FTF versus standard of care

Exclusion Criteria:

  • Pregnancy
  • Age <18 years
  • Patients with no access to texting or unable to engage via a text messaging service
  • Patients requiring fewer than three components of the infertility work-up
  • Patients presenting for second opinion with work-up completed
  • Patients seeking IVF for oocyte cryopreservation, PGT-M, or embryo banking
  • Non-English speaking

Study details
    Infertility

NCT07154888

University of Pennsylvania

15 October 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.